RNA Therapeutics in Heart Failure
Open Access
- 30 October 2025
- journal article
- review article
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (6) , 1540-1554
Abstract
RNA-based therapeutics, such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs) and messenger RNAs (mRNAs) are promising therapeutics that offer new avenues for targeting molecular pathways underlying heart failure (HF) pathogenesis. This review provides an overview of RNA therapeutics, detailing their mechanisms and potential applications in the treatment of HF. Key pathological processes in HF, including dysregulated calcium handling, myocardial fibrosis, oxidative stress, inflammation and aberrant signalling, are explored to identify how RNA-based therapeutics can be utilized to address these mechanisms. Preclinical studies demonstrating the potential of RNA therapeutics to modulate these pathways are discussed. In addition, the review identifies novel therapeutic targets of HF that may allow more precise and effective interventions, potentially reversing disease progression in HF. In this way, the potential of RNA therapeutics as a next-generation treatment strategy for HF are highlighted, offering hope for more targeted and personalized approaches for HF. Graphical AbstractKeywords
This publication has 181 references indexed in Scilit:
- Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohortNetherlands Heart Journal, 2025
- Circulating microRNAs and Cardiomyocyte Proliferation in Heart Failure Patients Related to 10 Years SurvivalESC Heart Failure, 2023
- Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14delCurrent Heart Failure Reports, 2022
- Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miR‐200 levels in extracellular vesiclesJournal of Extracellular Vesicles, 2022
- Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trialMuscle & Nerve, 2021
- Influences of Regulation of miR-126 on Inflammation,Th17/Treg Subpopulation Differentiation, and Lymphocyte Apoptosis through Caspase Signaling Pathway in SepsisInflammation, 2020
- MicroRNA‐214 exerts a Cardio‐protective effect by inhibition of fibrosisThe Anatomical Record, 2016
- MicroRNA-1 aggravates cardiac oxidative stress by post-transcriptional modification of the antioxidant networkCell Stress and Chaperones, 2015
- Micro‐RNA‐21 regulates TGF‐β‐induced myofibroblast differentiation by targeting PDCD4 in tumor‐stroma interactionInternational Journal of Cancer, 2011
- MONOCYTE CHEMOATTRACTANT PROTEIN 1 (MCP-1) GENE EXPRESSION IN DILATED CARDIOMYOPATHYCytokine, 1998